- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- Oversight failures and regulatory inertia in the U.S. drug approval process were exposed on August 3rd, involving the FDA and Merck.
The entities involved
Related events
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
- Providence Medical Technology, Inc. received 510(k) clearance from the FDA and plans to showcase its system at the Henry B. González Convention Center.
- FDA and Pfizer are seeking regulatory approval for their products.
- FDA provided guidance for HCW Biologics' IND application.
- Expertise is guiding drug development toward regulatory approval, involving the FDA and David Rubenstein.